来那度胺
嵌合抗原受体
多发性骨髓瘤
T细胞
抗原
细胞因子
癌症研究
生物
药理学
免疫学
免疫系统
作者
Melissa Works,Neha Soni,Collin Hauskins,Catherine Sierra,Alex Baturevych,Jon C. Jones,Wendy Curtis,Patrick Carlson,Timothy G. Johnstone,David Kugler,Ronald J. Hause,Yue Jiang,Lindsey Wimberly,Christopher R. Clouser,Heidi K. Jessup,Blythe Sather,Ruth A. Salmon,Michael O. Ports
出处
期刊:Molecular Cancer Therapeutics
[American Association for Cancer Research]
日期:2019-12-01
卷期号:18 (12): 2246-2257
被引量:61
标识
DOI:10.1158/1535-7163.mct-18-1146
摘要
Abstract Anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells have shown promising clinical responses in patients with relapsed/refractory multiple myeloma. Lenalidomide, an immunomodulatory drug, potentiates T cell functionality, drives antimyeloma activity, and alters the suppressive microenvironment; these properties may effectively combine with anti-BCMA CAR T cells to enhance function. Using an anti-BCMA CAR T, we demonstrated that lenalidomide enhances CAR T cell function in a concentration-dependent manner. Lenalidomide increased CAR T effector cytokine production, particularly under low CAR stimulation or in the presence of inhibitory ligand programmed cell death 1 ligand 1. Notably, lenalidomide also enhanced CAR T cytokine production, cytolytic activity, and activation profile relative to untreated CAR T cells in chronic stimulation assays. This unique potentiation of both short-term CAR T activity and long-term functionality during chronic stimulation prompted investigation of the molecular profile of lenalidomide-treated CAR T cells. Signatures from RNA sequencing and assay for transposase-accessible chromatin using sequencing indicated that pathways associated with T-helper 1 response, cytokine production, T cell activation, cell-cycle control, and cytoskeletal remodeling were altered with lenalidomide. Finally, study of lenalidomide and anti-BCMA CAR T cells in a murine, disseminated, multiple myeloma model indicated that lenalidomide increased CAR T cell counts in blood and significantly prolonged animal survival. In summary, preclinical studies demonstrated that lenalidomide potentiated CAR T activity in vivo in low-antigen or suppressive environments and delayed onset of functional exhaustion. These results support further investigation of lenalidomide and anti-BCMA CAR T cells in the clinic.
科研通智能强力驱动
Strongly Powered by AbleSci AI